Literature DB >> 23278853

High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD.

Fiona L Dignan1, Mike N Potter, Mark E Ethell, Matthew Taylor, Lily Lewis, Joy Brennan, Louise McNamara, Steve O Evans, Unell Riley, Faith E Davies, Claire E Dearden, Gareth J Morgan, Bronwen E Shaw.   

Abstract

Graft-versus-host disease (GvHD) is a common complication following haematopoietic stem cell transplant but little is published about the impact of this condition on hospital readmission rates. We report a retrospective analysis of readmission rates and associated costs in 187 consecutive allogeneic transplant patients to assess the impact of GvHD. The overall readmission rate was higher in patients with GvHD (86% (101/118) vs. 59% (41/69), p < 0.001). The readmission rate was higher both in the first 100 d from transplant (p = 0.02) and in the first year following transplant (p < 0.001). 151/455 (33%) of all readmission episodes occurred within 100 d of transplant. The mean number of inpatient days was significantly higher in patients with grade III/IV acute GvHD (101 d) compared with those with grade I/II GvHD (70 d; p = 0.003). The mean cost of readmission was higher in patients with GvHD (£28 860) than in non-GvHD patients (£13 405; p = 0.002) and in patients with grade III/IV GvHD (£40 012) compared with those patients with grade I/II GvHD (£24 560; p = 0.038). Survival was higher in those with grade I/II GvHD (55%) compared to grade III/IV GvHD (14%; p < 0.001). This study shows the high economic burden and poor overall survival associated with grade III/IV GvHD.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 23278853     DOI: 10.1111/ctr.12065

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  12 in total

1.  Quality of surgical care and readmission in elderly glioblastoma patients.

Authors:  Miriam Nuño; Diana Ly; Debraj Mukherjee; Alicia Ortega; Keith L Black; Chirag G Patil
Journal:  Neurooncol Pract       Date:  2014-05-19

2.  Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.

Authors:  M Kwon; G Bautista; P Balsalobre; I Sánchez-Ortega; P Montesinos; A Bermúdez; A de Laiglesia; P Herrera; C Martin; K Humala; A Zabalza; M Torres; L Bento; L L Corral; I Heras; D Serrano; I Buño; J Anguita; C Regidor; R Duarte; R Cabrera; J Gayoso; J L Diez-Martin
Journal:  Bone Marrow Transplant       Date:  2017-03-27       Impact factor: 5.483

3.  Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT.

Authors:  E Biagi; D Zama; C Nastasi; C Consolandi; J Fiori; S Rampelli; S Turroni; M Centanni; M Severgnini; C Peano; G de Bellis; G Basaglia; R Gotti; R Masetti; A Pession; P Brigidi; M Candela
Journal:  Bone Marrow Transplant       Date:  2015-04-20       Impact factor: 5.483

4.  Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis.

Authors:  Staci D Arnold; Zhezhen Jin; Stephen Sands; Monica Bhatia; Andrew L Kung; Prakash Satwani
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-20       Impact factor: 5.742

5.  The Cost of Hematopoietic Stem-Cell Transplantation in the United States.

Authors:  Michael S Broder; Tiffany P Quock; Eunice Chang; Sheila R Reddy; Rajni Agarwal-Hashmi; Sally Arai; Kathleen F Villa
Journal:  Am Health Drug Benefits       Date:  2017-10

6.  HIV cure strategies: how good must they be to improve on current antiretroviral therapy?

Authors:  Paul E Sax; Alexis Sypek; Bethany K Berkowitz; Bethany L Morris; Elena Losina; A David Paltiel; Kathleen A Kelly; George R Seage; Rochelle P Walensky; Milton C Weinstein; Joseph Eron; Kenneth A Freedberg
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

7.  Predicting Inpatient Readmission and Outpatient Admission in Elderly: A Population-Based Cohort Study.

Authors:  Kun-Pei Lin; Pei-Chun Chen; Ling-Ya Huang; Hsiu-Chen Mao; Ding-Cheng Derrick Chan
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

8.  Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant.

Authors:  Mary D Thoma; Jennifer Glejf; Eapen Jacob; Tanya J Huneke; Lori J DeCook; Nicci D Johnson; Mrinal M Patnaik; Mark R Litzow; William J Hogan; Laura F Newell; Rekha Chandran; Luis F Porrata; Shernan G Holtan
Journal:  BMC Hematol       Date:  2014-09-01

Review 9.  Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation.

Authors:  Emily South; Edward Cox; Nick Meader; Nerys Woolacott; Susan Griffin
Journal:  Pharmacoecon Open       Date:  2019-06

10.  Early unplanned readmission of neurosurgical patients after treatment of intracranial lesions: a comparison between surgical and non-surgical intervention group.

Authors:  Caroline Sander; Henry Oppermann; Ulf Nestler; Katharina Sander; Nikolaus von Dercks; Jürgen Meixensberger
Journal:  Acta Neurochir (Wien)       Date:  2020-08-15       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.